Vitamin D: Extraskeletal Health

Rheumatic Disease Clinics of North America

Volumn 38, Issue 1, 2012, Pages 141-160

  Holick, Michael F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diseases; Cancer; Cardiovascular; Diabetes; Extraskeletal effects; Psoriasis; Vitamin D

Indexed keywords

22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; CALCIPOTRIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; PLACEBO; TACALCITOL; VITAMIN D;

DRUG DOSE INCREASE; DRUG EFFECT; HEALTH STATUS; HUMAN; HYPERCALCEMIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL REQUIREMENT; PRELEUKEMIA; PRIORITY JOURNAL; PSORIASIS; REVIEW; RICKETS; SIDE EFFECT; SINGLE DRUG DOSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE;

EID: 84860008364     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2012.03.013     Document Type: Review

References (100)

1. Holick M.F. Phylogenetic and evolutionary aspects of vitamin D from phytoplankton to humans. Vertebrate endocrinology: fundamentals and biomedical implications 1989, vol. 3:7-43. Academic Press, Inc. (Harcourt Brace Jovanovich), Orlando (FL). P.K. Pang, M.P. Schreibman (Eds.).
2. Holick M.F. Vitamin D: a millennium perspective. J Cell Biochem 2003, 88:296-307.
3. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
4. Tangpricha V., Koutkia P., Rieke S.M., et al. Fortification of orange juice with vitamin D: a novel approach to enhance vitamin D nutritional health. Am J Clin Nutr 2003, 77:1478-1483.
5. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006, 116(8):2062-2072.
6. Rajakumar K., Greenspan S.L., Thomas S.B., et al. Solar ultraviolet radiation and vitamin D. A historical perspective. Am J Public Health 2007, 97(10):1746-1748.
7. Hess A.F. Collected writings, volume I 1936, Charles C. Thomas, Springfield (IL), 669-719.
8. Hoffman F.L. The mortality of cancer throughout the world 1915, Appendix E, Prudential Press, Newark (NJ).
9. Apperly F.L. The relation of solar radiation to cancer mortality in North America. Cancer Res 1941, 1:191-195.
10. Gorham E.D., Garland C.F., Garland F.C., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007, 32(3):210-216.
11. Jones G. Expanding role for Vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1α-hydroxylase in the classical and nonclassical actions of 1α,25-dihydroxyvitamin D3. Semin Dial 2007, 20(4):316-324.
12. Christakos S., Dhawan P., Liu Y., et al. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003, 88:695-705.
13. Dusso A.S., Brown A.J. Slatopolsky. Vitamin D. Am J Physiol Renal Physiol 2005, 289:F8-F28.
14. Stumpf W.E., Sar M., Reid F.A., et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979, 206:1188-1190.
15. Tanaka H., Abe E., Miyaura C., et al. 1,25-Dihydroxycholeciferol and human myeloid leukemia cell line (HL-60): The presence of cytosol receptor and induction of differentiation. Biochem J 1982, 204(3):713-719.
16. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
17. 3-1-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66:287-292.
18. 3. Cancer Epidemiol Biomarkers Prev 1998, 7:391-395.
19. Feldman D., Zhao X.Y., Krishnan A.V. Editorial/mini-review: vitamin D and prostate cancer. Endocrinology 2000, 141:5-9.
20. Gkonos P.J., London R., Hendler E.D. Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med 1984, 311:1683-1685.
21. 3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 1985, 60:960-966.
22. Tangpricha V., Flanagan J.N., Whitlatch L.W., et al. 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 2001, 357(9269):1673-1674.
23. 3 by a human small cell lung cell line. J Clin Endocrinol Metab 1994, 79(2):554-560.
24. Radermacher J., Diesel B., Seifert M., et al. Expression analysis of CYP27B1 in tumor biopsies and cell cultures. Anticancer Res 2006, 26:2683-2686.
25. Garland C.F., Garland F.C., Gorham E.D. Can colon cancer incidence and death rates be reduced with calcium and vitamin D?. Am J Clin Nutr 1991, 54:93S-201S.
26. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Cancer 1992, 70:2861-2869.
27. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
28. Bertone-Johnson E.R., Chen W.Y., Holick M.F., et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1991-1997.
29. Moan J., Porojnicu A.C., Dahlback A., et al. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci USA 2008, 105(2):668-673.
30. Grant W.B. Lower vitamin-D production from solar ultraviolet-B Irradiance may explain some differences in cancer survival rates. J Natl Med Assoc 2006, 98(3):357-364.
31. Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 2007, 103(3-5):708-711.
32. Ahonen M.H., Tenkanen L., Teppo L., et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
33. Giovannucci E., Liu Y., Rimm E.B., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98(7):451-459.
34. Luscombe C.J., Fryer A.A., French M.E., et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001, 358:641-642.
35. Knight J.A., Lesosky M., Barnett H., et al. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):422-499.
36. Wactawski-Wende J., Kotchen J.M., Anderson G.L., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.
37. Holick M.F. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006, 354(21):2287.
38. Lappe J.M., Travers-Gustafson D., Davies K.M., et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85(6):1586-1591.
39. Giovannucci E., Liu Y., Willett W.C. Cancer incidence and mortality and vitamin D in black ad white male health professionals. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2467-2472.
40. Bibuld D. Health disparities and vitamin D. Humana Press Inc 2009, 7(1):63-76.
41. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
42. Palmer H.G., Larriba M.J., Garcia J.M., et al. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 2004, 10:917-919.
43. Bikle D.D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009, 94(1):26-34.
44. Koeffler H.P., Hirjik J., Iti L., et al. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985, 69:1399-1407.
45. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-257.
46. Spina C., Tangpricha V., Yao M., et al. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J Steroid Biochem Mol Biol 2005, 97:111-120.
47. Spina C.S., Tangpricha V., Uskokovic M., et al. Vitamin D and cancer. Anticancer Res 2006, 26(4a):2515-2524.
48. Woo T.C.S., Choo R., Jamieson M., et al. Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005, 51(1):32-36.
49. 3 (calcitriol). J Urol 1998, 159:2035-2040.
50. Beer T.M., Javle M.M., Ryan C.W., et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007, 59:581-587.
51. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003, 14:423-430.
52. Zhao X.Y., Feldman D. The role of vitamin D in prostate cancer. Steroids 2001, 66:293-300.
53. Holick M.F. Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 2008, 3:1548-1554.
54. Holick M.F., Chen T.C., Sauter E.R. Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res 2007, 22(S2):V28-V33.
55. 3) for the treatment of psoriasis. Br J Dermatol 1996, 134:238-246.
56. 3 analogue MC 903. Arch Dermatol 1989, 125:1647-1652.
57. 3 and its analogues in the treatment of psoriasis. Retinoids 1998, 14:7-12.
58. Embry A.F., Snowdon L.R., Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000, 48:271-272.
59. Hernán M.A., Olek M.J., Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999, 51:1711-1718.
60. Mohr S.B., Garland C.F., Gorham E.D., et al. The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 2008, 51(8):1391-1398.
61. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
62. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62(1):60-65.
63. Merlino L.A., Curtis J., Mikuls T.R., et al. Iowa Women's Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis. Arthritis Rheum 2004, 50(1):72-77.
64. Hypponen E., Laara E., Jarvelin M.-R., et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
65. Camargo C.A., Rifas-Shiman S.L., Litonjua A.A., et al. Maternal intake of vitamin D during pregnancy and risk of recurrent wheeze in children at 3 y of age. Am J Clin Nutr 2007, 85(3):788-795.
66. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Clin Investig 2005, 128:3792-3798.
67. 3, and the immune system. Am J Clin Nutr 2004, 80(Suppl):1717S-1720S.
68. Adorini L., Giarratana N., Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004, 16:127-134.
69. Daniel C., Satory N.A., Zahn N., et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008, 324:23-33.
70. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 3:1770-1773.
71. White J.H. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 2008, 76(9):3837-3843.
72. Albert P.J., Proal A.D., Marshall T.G. Vitamin D: the alternative hypothesis. Autoimmun Rev 2009, 8:639-644.
73. 3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci 1996, 93:7861-7864.
74. Cantorna M.T., Munsick C., Bemiss C., et al. 1,25-dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130:2648-2652.
75. Linday L.A., Shindledecker R.D., Dolitsky J.N., et al. Plasma 25-hydroxyvitamin D levels in young children undergoing placement of tympanostomy tubes. Ann Otol Rhinol Laryngol 2008, 117:740-744.
76. Ginde A.A., Mansbach J.M., Camargo C.A. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the third national health and nutrition examination survey. Arch Intern Med 2009, 169(4):384-390.
77. Cannell J.J., Vieth R., Umhau J.C., et al. Epidemic influenza and vitamin D. Epidemiol Infect 2006, 134(6):1129-1140.
78. 3 supplementation in African American women. Arch Intern Med 2005, 165:1618-1623.
79. Adams J.S., Hewison M. Hypercalcemia caused by granuloma-forming disorders. Primer on the metabolic bone diseases and disorders of mineral metabolism 2006, 200-202. American Society for Bone and Mineral Research, Washington, DC. 6th edition. M.J. Favus (Ed.).
80. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117(4):503-511.
81. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167(16):1730-1737.
82. Rostand S.G. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997, 30(2 Pt 1):150-156.
83. Krause R., Buhring M., Hopfenmuller W., et al. Ultraviolet B and blood pressure. Lancet 1998, 352(9129):709-710.
84. 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110(2):229-238.
85. Lee J.H., O'Keefe J.H., Bell D., et al. Vitamin D Deficiency: an important, common, and easily treatable cardiovascular risk factor. J Am Coll Cardiol 2008, 52:1949-1956.
86. Zittermann A., Schleithoff S.S., Tenderich G., et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 2003, 41:105-112.
87. 2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120(8):687-712.
88. Holick M.F. Vitamin D. The underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002, 9:87-98.
89. Chiu K.C., Chu A., Go V.L.W., et al. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr 2004, 79:820-825.
90. Pittas A.G., Dawson-Hughes B., Li T., et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006, 29(3):650-656.
91. Scragg R., Sowers M., Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 2004, 27:2813-2818.
92. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board, Institute of medicine Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride 1999, National Academy Press, Washington, DC.
93. Jeans P.C. Vitamin D. JAMA 1950, 1243:177-181.
94. Grant W.B., Holick M.F. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005, 10:94-111.
95. 3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008, 93(3):677-681.
96. Heaney R.P., Davies K.M., Chen T.C., et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77:204-210.
97. Holick M.F., Chen T.C. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008, 87(4):1080S-1086S.
98. Wagner C.L., Greeer F.R., Section on Breastfeeeding and Committee on Nutrition Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122:1142-1152.
99. El-Hajj Fuleihan G., Nabulsi M., Tamim H., et al. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin Endocrinol Metab 2006, 91:405-412.
100. 2 treatment for vitamin D deficiency and insufficiency for up to 6 years. Arch Intern Med 2009, 169:1806-1808.